Nature Medicine, Published online: 11 May 2026; doi:10.1038/s41591-026-04400-y
A first-in-human trial involving selective removal of the placental protein sFlt-1 in preterm pre-eclampsia provides critical safety data, and could mark the beginning of a new era of targeted therapy for this potentially lethal pregnancy complication.
